Literature DB >> 13271342

Incorporation of 4-amino-5-imidazolecarboxamide-4-C13 into uric acid in the normal human.

J E SEEGMILLER, L LASTER, D STETTEN.   

Abstract

Entities:  

Keywords:  IMIDAZOLINES/metabolism; URIC ACID/metabolism

Mesh:

Substances:

Year:  1955        PMID: 13271342

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


× No keyword cloud information.
  10 in total

1.  Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-L-norleucine.

Authors:  A I GRAYZEL; J E SEEGMILLER; E LOVE
Journal:  J Clin Invest       Date:  1960-03       Impact factor: 14.808

2.  Overproduction of uric acid as the cause of hyperuricemia in primary gout.

Authors:  J B WYNGAARDEN
Journal:  J Clin Invest       Date:  1957-10       Impact factor: 14.808

3.  Physiopathology, clinical manifestations, & treatment of gout. 2. Clinical & therapeutic studies.

Authors:  S DE SEZE; A RYCKEWAERT; J LEVERNIEUX; R MARTEAU
Journal:  Ann Rheum Dis       Date:  1958-03       Impact factor: 19.103

4.  GOUT.

Authors: 
Journal:  Br Med J       Date:  1958-03-29

5.  Contributions of Lesch-Nyhan syndrome to the understanding of purine metabolism.

Authors:  J E Seegmiller
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

Review 6.  The study of human intermediary purine metabolism and its regulation.

Authors:  J E Seegmiller
Journal:  Proc R Soc Med       Date:  1966-04

7.  Hyperuricaemia: some biochemical aspects.

Authors:  R W Watts
Journal:  Proc R Soc Med       Date:  1969-08

8.  Uric acid production with particular reference to the role of xanthine oxidase and its inhibition.

Authors:  R W Watts
Journal:  Proc R Soc Med       Date:  1966-04

9.  Current concepts of hyperuricemia and gout.

Authors:  J R Klinenberg
Journal:  Calif Med       Date:  1969-03

10.  Suppression of glycine-15N incorporation into urinary uric acid by adenine-8-13C in normal and gouty subjects.

Authors:  J E Seegmiller; J R Klinenberg; J Miller; R W Watts
Journal:  J Clin Invest       Date:  1968-05       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.